[18F]Fluorodeoxyglucose PET/CT and prediction of histopathological response to neoadjuvant chemotherapy for adenocarcinoma of the oesophagus and oesophagogastric junction. BJS 2018; 105: 419-428.
Published: 8th February 2018
Authors: T. Harustiak, M. Zemanova, P. Fencl, L. Hornofova, A. Pazdro, M. Snajdauf et al.
The aim of this prospective study was to assess whether [18F]fluorodeoxyglucose PET can be used to predict histopathological response early in the course of neoadjuvant chemotherapy in patients with adenocarcinoma of the oesophagus and oesophagogastric junction.
Following the PET response criteria in solid tumours (PERCIST 1.0) as a standardized method for semiquantitative assessment of metabolic response, FDG‐PET/CT was performed before (PET1) and after (PET2) initiation of the first cycle of chemotherapy. The relative changes in the peak standardized uptake value (ΔSUL) and total lesion glycolysis (ΔTLG) between PET1 and PET2 were correlated with histopathological response, defined as less than 50 per cent viable tumour cells in the resection specimen. A receiver operating characteristic (ROC) curve analysis was used to identify the optimal cut‐off value with the highest accuracy of histopathological response prediction.
PET2 was performed a median of 16 (range 12–22) days after the start of chemotherapy. Some 27 of 90 patients who underwent surgery had a histopathological response. There was no association between the median ΔSUL or median ΔTLG and the histopathological response. A
FDG‐PET/CT after the first cycle of chemotherapy does not predict histopathological response in patients with adenocarcinoma of the oesophagus and oesophagogastric junction.Full text
You may also be interested in
Authors: M. van Putten, S. D. Nelen, V. E. P. P. Lemmens, J. H. M. B. Stoot, H. H. Hartgrink, S. S. Gisbertz et al.
Notes: Practise makes perfect?
Oesophagectomy with or without supraclavicular lymphadenectomy after neoadjuvant treatment for squamous cell carcinoma of the oesophagus.
Authors: S. Mine, M. Watanabe, K. Kumagai, A. Okamura, K. Yamashita, M. Hayami et al.
Notes: Extended dissection not needed
Authors: J. Zheng, S.‐H. Xie, G. Santoni, J. Lagergren
Notes: Diabetes increases risk
Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.
Authors: A. R. Davies, D. Myoteri, J. Zylstra, C. R. Baker, W. Wulaningsih, M. Van Hemelrijck et al.
Notes: Nodal response predicts survival
Network meta‐analysis of surgical management of gastro‐oesophageal reflux disease in adults. BJS 2018; 105: 1398-1407.
Authors: M. A. Amer, M. D. Smith, C. H. Khoo, G. P. Herbison, J. L. McCall
Meta‐analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. BJS 2018; 105: 1408-1416.
Authors: N. T. E. Bird, A. McKenna, J. Dodd, G. Poston, R. Jones, H. Malik et al.
Notes: Tumour biology is important
Randomized clinical trial
Multicentre factorial randomized clinical trial of perioperative immunonutrition versus standard nutrition for patients undergoing surgical resection of oesophageal cancer. BJS 2018; 105: 1262-1272.
Authors: L. A. Mudge, D. I. Watson, B. M. Smithers, E. A. Isenring, L. Smith, G. G. Jamieson et al.
Notes: No difference
Detection of carcinoembryonic antigen in peritoneal fluid of patients undergoing laparoscopic distal gastrectomy with complete mesogastric excision. BJS 2018; 105: 1471-1479.
Authors: D. Xie, Y. Wang, J. Shen, J. Hu, P. Yin, J. Gong et al.
Notes: Careful surgery, fewer free cancer cells
Authors: B. J. Noordman, E. W. de Bekker‐Grob, P. P. L. O. Coene, E. van der Harst, S. M. Lagarde, J. Shapiro et al.
Notes: Organ preservation preferred
Authors: M. T. Adil, V. Jain, F. Rashid, O. Al‐taan, D. Whitelaw, P. Jambulingam et al.
Notes: Bariatric surgery improves physical function
Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. BJS 2018; 105: 1480-1486.
Authors: B.‐H. Min, M. Hong, J. H. Lee, P.‐L. Rhee, T. S. Sohn, S. Kim et al.